Jim Cramer Highlights the Woes of Pfizer and the Drug Sector

Pfizer Inc. (NYSE:PFE) is one of the latest stocks on Jim Cramer’s radar. Cramer noted that the company could not perform as its entire industry is going through a tough time. He remarked:

“…We also have a huge number of stocks that are sinking under their own weight, high-quality companies, real companies that are historically cheap and getting cheaper. Consider Pfizer. Yes, plain old, boring Pfizer.

This morning, this high-quality drug company reported earning 87 cents a share. Wall Street was only looking for 63. Higher than expected revenue, too. Clean numbers, solid numbers, yet it didn’t matter. The entire drug sector is so despised, Pfizer finished the session down 1.5%. Darn thing sells for just eight times earnings.”

Pfizer Inc. (NYSE:PFE) manufactures medicines and vaccines across multiple therapeutic areas, including cardiovascular, infectious diseases, oncology, and immunology. The company’s leading brands include Comirnaty, Paxlovid, Eliquis, Prevnar, Ibrance, and Xeljanz. During the October 31 episode, Cramer mentioned the stock and said:

“Now, will Pfizer break out from the $25 level? Oh, it’s been a dull run for this former growth drug stock as shareholders seem to be satisfied with a 7% yield, not much price appreciation. I like growth, but that dividend seems safe, and it’s backed up by cash flow. On Tuesday morning, we’ll find out if Pfizer’s going to be more of a stock and less of a bond equivalent.”

While we acknowledge the potential of PFE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.